Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQW051 for L-dopa Induced Dyskinesias in Parkinson's Disease
NCT01474421Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of AQW051 in dyskinesia, sponsored by Novartis. Primary endpoints: Modified Abnormal Involuntary Movement Scale at Day 28, Unified Parkinson's Disease Rating Scale Part III at Day 28 and 1 more. Started Sep 2011; status: completed.
02
Drugs
AQW051
03
Conditions
dyskinesia
Beyond the preview
Go deeper on NCT01474421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01474421.